Most Clicked AABB SmartBrief Stories

1. Scientists create silk matrix for laboratory production of platelets

AABB SmartBrief | Feb 20, 2015

Tufts University scientists have developed a silk-based, three-dimensional system for the culture of platelet-producing megakaryocytes, according to a study in the journal Blood. The method could be used to study platelet production, and it has the potential to be developed for clinical use, according to the researchers. (India) (02/19)

2. Study examines bleeding risks of NSAIDS combined with anti-clotting drugs

AABB SmartBrief | Feb 25, 2015

Taking nonsteroidal anti-inflammatory drugs with antithrombotic drugs was associated with increased risk of major bleeding, a second heart attack and death for patients with a history of heart attacks, according to a study in the Journal of the American Medical Association. An analysis of the records of more than 60,000 heart attack survivors found bleeding events were about twice as likely for patients who had taken an NSAID along with clot-preventing drugs. Reuters (02/24)

3. FDA proposes adverse-event reporting guidance for cellular, tissue products

AABB SmartBrief | Feb 20, 2015

The FDA has released new draft guidelines describing the kinds of adverse events related to the use of human cells, tissues, and cellular and tissue-based products that should be reported to the FDA, and how establishments should report the events. The report should be filed by the establishment that makes HCT/Ps available for distribution, and it should be done within 15 days of the discovery of the event, the agency said. Regulatory Focus (02/19)

4. Pathogen reduction technologies featured in February issue of AABB News

AABB SmartBrief | Feb 24, 2015

The February issue of AABB News highlights the use of pathogen reduction, or PR, technologies to prevent the spread of infectious diseases. One article in the issue describes how researchers and clinicians are using these technologies in Puerto Rico to reduce the risk of spreading chikungunya and dengue viruses through blood products. In December, FDA approved the first pathogen reduction system for platelets and plasma authorized for use in the United States. A second article focuses on research aimed at treating whole blood with PR technologies to use in circumstances where only unscreened whole blood is available, such as military deployments. Blank (02/24)

5. Dental stem cells converted into corneal stromal cells

AABB SmartBrief | Feb 24, 2015

University of Pittsburgh ophthalmology researchers have converted stem cells extracted from the dental pulp of wisdom teeth into corneal stromal cells, according to a study in the journal Stem Cells Translational Medicine. The study team transplanted the cells into the corneas of healthy mice. Genetic Engineering & Biotechnology News (02/23) (02/23)

6. Retinal tissue developed from stem cells, researchers report

AABB SmartBrief | Feb 23, 2015

Scientists at the Riken Center for Developmental Biology and Sumitomo Chemical have devised a method of engineering three-dimensional retinal tissue from human stem cells. The cultured tissue included the ciliary margin, where stem cells produce photoreceptor and nerve cells. The results of the study were reported in the journal Nature Communications. Japan Times, The (02/20)

7. T cell therapy enters clinical testing for brain tumors

AABB SmartBrief | Feb 20, 2015

Scientists at the University of Pennsylvania's Abramson Cancer Center have begun a clinical study using T cells engineered to bind to the surface of cells that express the protein EGFRvIII for the treatment of brain cancer. A similar technique is being explored for possible use against leukemia. The study team's findings were reported in the journal Science Translational Medicine. United Press International (02/18)

8. Drug shows efficacy in addressing infantile hemangioma

AABB SmartBrief | Feb 23, 2015

Data on 460 infants with infantile hemangioma showed 88% of those treated with propranolol exhibited improvements at five weeks, compared with 5% of those on placebo treatment. Sixty percent of patients in the treatment group had their birthmarks almost or completely disappear, compared with only 4% in the placebo cohort. The results appear in the New England Journal of Medicine. (02/19)

9. Clostridium difficile germinates in digestive tract within 24 hours

AABB SmartBrief | Feb 24, 2015

Researchers have found that Clostridium difficile spores develop into toxin-producing, diarrhea-inducing cells in the large intestine of antibiotic-treated mice within 24 hours. The study, which appeared in the journal Infection and Immunity, found that C. difficile became the most dominant gut bacteria within 36 hours of exposure in mice whose bacterial colonies had been disrupted by antibiotics. Medical News Today (02/23)

10. AABB CareerLink matches candidates with jobs in patient blood management, transfusion medicine and cellular therapies

AABB SmartBrief | Feb 23, 2015

Blood bank manager. Lab supervisor. Medical director. These are just a few of the open positions listed on the AABB CareerLink site. CareerLink provides an easy and efficient way to connect those seeking employment in patient blood management, transfusion medicine and cellular therapies with organizations that have openings in those areas. Job seekers can view vacancies by category and location, post their resume for prospective employers and sign up to receive e-mail alerts when new positions are added to the site. Employers can view applicants' resumes and post job descriptions and other salient information about open positions. The site also provides job seekers with expert advice on how to write compelling resumes and cover letters, network for success and stand out in a job interview. Blank (02/08)

Sign up for AABB SmartBrief

Designed specifically for the transfusion medicine and cellular therapy community, AABB SmartBrief is a FREE, daily e-mail newsletter. It provides a summary of the most important news in our field to members of AABB and beyond. To save time and stay smart, sign up today to receive AABB SmartBrief, free of charge. Learn more